Savient Pharmaceuticals, Inc.
One Tower Center
Fourteenth Floor
East Brunswick,
NJ 08816
United States - Map
Phone: 732-418-9300
Fax: 732-418-0570
Web Site: http://www.savientpharma.com
| Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers. The company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Paul R. Hamelin R.Ph., 54
Pres |
$
344.00K |
$
276.00K | Mr. Philip K. Yachmetz J.D, 52
Sr. VP, Sec. and Gen. Counsel |
$
388.00K |
$
520.00K | Mr. David G. Gionco ,
Chief Financial Officer, VP and Treasurer |
N/A
| N/A | Mr. Peter Clarke Ph.D., 49
VP of Manufacturing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
Profile
